All articles by Abigail Beaney

Abigail Beaney

Abigail Beaney is a pharmaceutical reporter for the Clinical Trials Arena. Abigail holds a BA (Hons) in Journalism from the University of Central Lancashire. Abigail has an expertise in trial design, cell and gene therapies and neurodegenerative diseases. Contact Abigail

Surrozen drops hepatitis drug after Phase I flop

Surrozen is dropping its sole clinical asset after the drug failed at Phase I, as the company considers a move…
Podcast: How will biotech and biopharma manage with more funding cuts?

The biotech and biopharma industry has struggled in recent years with a lack of investment. While GlobalData has tracked an…
Rising Sirturo resistance highlights urgent need for new TB therapies

There have been widespread reports that more effort and funding is needed to combat the TB crisis. As more cases…
MacroGenics axes ADC drug following Phase II failure in prostate cancer

MacroGenics is axing the development of one of its antibody-drug conjugates (ADC) after it flopped in a Phase II study…
Funding drought: how can biotech and biopharma keep trials running?

It’s widely known in the industry that private investment in biotech and biopharma has been down in recent years. Whilst…

Roche’s discontinued Alzheimer’s drug shows signs of preventing onset

Roche’s discontinued Alzheimer’s disease drug has shown signs that it could prevent onset of the disease. The Phase II/III Knight…
Innovent & HUTCHMED seek approval of kidney cancer combo after Phase II/III trial

Chinese-based Innovent Biologics and HUTCHMED are eyeing approval for their cancer combination after a joint Phase II/III kidney cancer trial…
AstraZeneca’s $1bn hypoparathyroidism drug achieves success at Phase III

UK-based AstraZeneca’s acquired rare disease drug has met the primary endpoint in a Phase III trial in patients with chronic…
Scholar Rock SMA drug shows muscle function benefit

Scholar Rock’s spinal muscular atrophy (SMA) therapy has shown benefit in muscle function in children under 12 in a pivotal…
MSD to push for approval of HIV combo after Phase III success

Merck & Co (MSD) is looking to file for approval of its human immunodeficiency virus (HIV) treatment after two positive…